Prostate Cancer

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

The FDA has approved a 3-month version of leuprolide mesylate for patients with advanced prostate cancer.

David Olmos, MD, PhD, discusses how data on the incidence of HRR alterations in metastatic prostate cancer can inform future research.

David Olmos, MD, PhD, discusses CAPTURE study findings on the prevalence of HRR mutations in mHSPC, highlighting prognostic impact and outcomes.

Health Canada has granted marketing authorization to darolutamide for the treatment of adult patients with metastatic castration-sensitive prostate cancer.

Matthew R. Smith, MD, PhD, discusses how PARP inhibition and radioligand therapies are shaping treatment decisions in advanced prostate cancer.

Clinicians spanning a spectrum of cancer subtypes discuss how they are currently using artificial intelligence in their daily practice.

Matthew R. Smith, MD, PhD, discusses findings from the ARANOTE trial that confirm the efficacy of darolutamide plus ADT in mCSPC.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

Gerhardt Attard, MD, PhD, FRCP, discusses niraparib plus abiraterone acetate and prednisone in mCSPC with HRR gene alterations.

Panelists discuss how successful metastatic castration-sensitive prostate cancer (mCSPC) management requires balancing cancer control with quality-of-life preservation, emphasizing the need for better tools to measure patient-reported outcomes, comprehensive survivorship care addressing cardiovascular and bone health, and personalized approaches that help patients understand their prognosis while maintaining their ability to thrive during treatment.

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

The FDA accepted the NDA seeking the approval of a new formulation of piflufolastat F 18 in prostate cancer.

Panelists discuss how quality-of-life considerations are paramount in treatment selection for patients with metastatic castration-sensitive prostate cancer (mCSPC), with data showing that achieving ultralow prostate-specific antigen (PSA) levels correlates with better quality-of-life outcomes and that tolerability profiles, particularly regarding fatigue and drug-drug interactions, significantly impact daily patient experience.

Panelists discuss how managing patients with suboptimal prostate-specific antigen (PSA) response or rising PSA requires careful consideration of PSA kinetics, doubling time, duration of prior response, and imaging findings to determine whether to continue monitoring, add therapy, or transition to castration-resistant treatment approaches.

The phase 1/2 CaRe Prostate trial examining INKmune in patients with metastatic CRPC has met its primary and secondary end points.

Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Panelists discuss how data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) demonstrates that achieving a prostate-specific antigen (PSA) threshold below 0.2 ng/mL at 6 to 12 months is associated with improved progression-free survival and overall survival regardless of treatment regimen.

Panelists discuss how prostate-specific antigen (PSA) nadir serves as a crucial prognostic marker in metastatic castration-sensitive prostate cancer (mCSPC), with faster drops to lower levels (particularly below 0.2) correlating with better outcomes, whereas imaging frequency should be customized based on clinical status and PSA kinetics.

Jue Wang, MD, outlines how prolonged androgen suppression may drive prostate cancer evolution.

Jue Wang, MD, discusses persistent gaps between clinical advances and real-world care and the evolving role of personalized treatment strategies in mCRPC.